You are here: Home ยป Archives for NASDAQ

Fortrea stellt „Fortrea Intelligent Technology™“ vor, um Sponsoren und Studienzentren dabei zu unterstützen, klinische Studien intelligenter und integrierter durchzuführen

Highlights:

  • Entwickelt, um die Abläufe bei klinischen Studien für Sponsoren, Studienzentren und Studienteams zu optimieren
  • Personenorientierte, KI-gestützte Lösungen automatisieren Arbeitsabläufe und optimieren die Überwachung, um die Geschwindigkeit, Vorhersehbarkeit und Qualität klinischer Studien zu verbessern
  • Baut auf der Flaggschiff-Plattform Xcellerate® von Fortrea auf, um rollenbasierte Einblicke nahezu in Echtzeit zu liefern

DURHAM, North Carolina, April 08, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), ein weltweit führendes Auftragsforschungsinstitut (CRO), hat heute Fortrea Intelligent Technology™(FIT) vorgestellt, eine Suite innovativer Technologielösungen, die darauf ausgelegt sind, den Ablauf klinischer Studien zu revolutionieren.

Durch die Integration von personenorientierten, KI-gestützten Lösungen, die Arbeitsabläufe automatisieren, die Überwachung optimieren und die Produktivität steigern, unterstützt FIT Sponsoren, Prüfzentren und Fortrea-Projektteams dabei, klinische Studien schneller, mit höherer Vorhersehbarkeit, Flexibilität und Qualität durchzuführen.

Eine innovative, intelligente Suite klinischer Lösungen
FIT umfasst wesentliche Verbesserungen der bekannten Fortrea-Angebote, darunter die preisgekrönte Xcellerate®-Plattform, sowie neu eingeführte Lösungen, die darauf ausgelegt sind, alle Prozesse innerhalb des Studien-Ökosystems zu integrieren.

Die Suite bietet Anwendungen für Kunden aus den Bereichen Biopharma und Biotechnologie in den Bereichen klinische Pharmakologie, klinische Entwicklung und Entwicklung medizinischer Geräte und kann sowohl im Full-Service- als auch im Functional-Service-Modell eingesetzt werden, wobei ausgewählte Komponenten als Software-as-a-Service (SaaS) verfügbar sind.

Die FIT-Lösungen gliedern sich in drei Säulen:

  • Lebenszyklus: Klinische Studien schneller und sicherer durchführen
    Lösungen, die Sponsoren und Studienzentren dabei unterstützen, klinische Studien in jeder Phase der klinischen Entwicklung voranzubringen. Sie tragen dazu bei, klinische Studien zu beschleunigen, indem sie wichtige Schritte automatisieren – von der Vorbereitungsphase bis zum endgültigen eTMF.
  • Vorausschau: Daten in umsetzbare Erkenntnisse verwandeln
    Lösungen, die Daten in Vorausschau umwandeln und so eine schnellere Entscheidungsfindung sowie eine proaktive Risikominderung ermöglichen. Sie bieten Transparenz, Trendanalysen und Risikominimierung durch intuitive Dashboards, die sichere Entscheidungen nahezu in Echtzeit sowie eine vereinfachte Überwachung ermöglichen.
  • Begleitung: Studien-Teams dabei unterstützen, intelligenter zu arbeiten
    Personenorientierte, KI-gestützte Lösungen, die einen produktiveren und effizienteren Ablauf klinischer Studien ermöglichen. Trägt dazu bei, die Durchführung von Studien zu optimieren, die Produktivität zu steigern und die Zusammenarbeit zu fördern.

„Wir befinden uns in einer bemerkenswerten Zeit, in der die Entwicklung klinischer Studien mit beispiellosen technologischen Fortschritten einhergeht. Fortrea Intelligent Technology steht genau an dieser Schnittstelle“, sagt der Chief Information Officer Alejandro Martinez Galindo. „Auf der Grundlage jahrzehntelanger Branchenerfahrung und direkter Rückmeldungen von Sponsoren und Prüfzentren bietet FIT menschenorientierte Lösungen, die es Sponsoren und Prüfzentren ermöglichen, klinische Studien effizienter, mit größerer Sicherheit und geringerem Risiko durchzuführen.“

Xcellerate® bildet das Fundament der Intelligent Suite
Xcellerate®, die Plattform von Fortrea für risikobasiertes Qualitätsmanagement (RBQM), zentrale Überwachung und Aufsicht – die Grundlage des FIT-Angebots.

Die jüngsten Verbesserungen sorgen für eine moderne, intuitive Benutzererfahrung, die Daten aus dem gesamten Studienumfeld integriert und so rollenbasierte Einblicke nahezu in Echtzeit liefert. Dank integrierter KI und maschinellem Lernen kann Xcellerate® komplexe Muster analysieren, Vorhersagesignale generieren und automatisierte Arbeitsabläufe auslösen. Dadurch wird der manuelle Aufwand reduziert, sodass sich die Teams auf die entscheidenden menschlichen Einschätzungen konzentrieren können, die für eine erfolgreiche klinische Forschung erforderlich sind.

„Wir gehen davon aus, dass diese Verbesserungen an Xcellerate® und die erweiterte FIT-Plattform für unsere Studienteams und unsere Kunden bahnbrechende Neuerungen darstellen werden“, so Mark Morais, Chief Operating Officer und President, Clinical Development. „Durch den verantwortungsvollen und ethischen Einsatz von KI tragen diese Technologien zu einem stärkeren Forschungsökosystem bei und ermöglichen es, schneller auf die Erkenntnisse aus den Daten zu reagieren – all dies kann entscheidend dazu beitragen, lebensverändernde Therapien schneller und effizienter zu den Patienten zu bringen.“

Fortrea baut das Portfolio von Fortrea Intelligent Technology weiter aus; weitere Lösungen sollen in Zukunft auf den Markt kommen.

Über Fortrea
Fortrea (Nasdaq: FTRE) ist ein weltweit führender Anbieter von Lösungen für die klinische Entwicklung in der Life-Sciences-Branche. Wir arbeiten mit aufstrebenden und großen biopharmazeutischen, biotechnologischen, medizintechnischen und diagnostischen Unternehmen zusammen, um Innovationen im Gesundheitswesen voranzutreiben, die das Angebot lebensverändernder Therapien für Patienten beschleunigen. Fortrea bietet das Management von klinischen Studien der Phasen I–IV, klinische Pharmakologie sowie Beratungsdienste an. Die Lösungen von Fortrea basieren auf drei Jahrzehnten Erfahrung in mehr als 20 Therapiegebieten, einer Leidenschaft für wissenschaftliche Strenge, außergewöhnlichen Erkenntnissen und einem starken Netzwerk von Prüfzentren. Unser talentiertes und vielfältiges Team, das in rund 100 Ländern tätig ist, ist so aufgestellt, dass es Kunden weltweit maßgeschneiderte und flexible Lösungen bieten kann. Erfahren Sie unter Fortrea.com mehr darüber, wie Fortrea die Arzneimittelentwicklung optimiert, und folgen Sie uns auf LinkedIn, X und Bluesky.

Ansprechpartner bei Fortrea:
Jennifer Minx (Medien) – 919-410-4195, [email protected]
Kate Dillon (Medien) – 646-818-9115, [email protected]
Tracy Krumme (Investoren) – 984-385-6707, [email protected]


GLOBENEWSWIRE (Distribution ID 9685923)

Fortrea Lança Fortrea Intelligent Technology™ para Ajudar Patrocinadores e Sites a Executar Testes Mais Inteligentes e Integrados

Destaques:

  • Criada para transformar as operações de ensaios clínicos de patrocinadores, locais e equipes de estudo
  • Soluções orientadas por personas e impulsionadas por IA automatizam fluxos de trabalho e otimizam a supervisão, auxiliando a melhoria da velocidade, previsibilidade e qualidade dos ensaios
  • Baseada na Xcellerate ®, principal plataforma da Fortrea, para fornecer insights quase em tempo real e baseados em funções

DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa clínica (CRO), lançou hoje Fortrea Intelligent Technology™(FIT), um conjunto de soluções tecnológicas inovadoras desenvolvidas para transformar as operações de ensaios clínicos.

Por meio da integração das soluções orientadas por personas e impulsionadas por IA que automatizam fluxos de trabalho, agilizam a supervisão e elevam a produtividade, a FIT ajuda a possibilitar que patrocinadores, centros de investigação e equipes de projeto da Fortrea realizem testes mais rapidamente, com maior previsibilidade, agilidade e qualidade.

Uma Suíte de Soluções Clínicas Inovadoras e Inteligentes
FIT incorpora grandes aprimoramentos nas ofertas da Fortrea, incluindo a premiada plataforma Xcellerate ®, juntamente com as novas soluções desenvolvidas para integrar todos os processos do ecossistema de testes.

A suíte oferece aplicações para clientes dos setores biofarmacêutico e de biotecnologia, abrangendo farmacologia e desenvolvimento clínico, e desenvolvimento de dispositivos médicos. Pode ser implementada tanto em modelos de serviço completo quanto de serviço funcional, com componentes selecionados disponíveis como Software como Serviço (SaaS).

As soluções FIT são organizadas em três pilares:

  • Ciclo de vida: Fornecimento Mais Rápido de Testes Confiáveis
    Soluções que ajudam os patrocinadores e os centros de pesquisa a realizar ensaios clínicos em cada etapa da jornada do desenvolvimento clínico. Também ajudam a acelerar os ensaios clínicos, por meio da automatização das principais etapas, desde a pré-adjudicação até o eTMF final.
  • Previsão: Transformação de Dados em Insights Acionáveis
    Soluções que transformam dados em previsão, ajudando a possibilitar uma tomada de decisão mais rápida e uma mitigação proativa de riscos. Proporcionam clareza, análise de tendências e mitigação de riscos com painéis intuitivos que viabilizam decisões confiantes e quase em tempo real, além de uma supervisão simplificada.
  • Companheira: Capacitação das Equipes de Estudo para um Trabalho Mais Inteligente
    Soluções baseadas em IA e orientadas por persona que apoiam operações de ensaios clínicos mais produtivas e eficientes. Ajudam a agilizar a entrega de estudos e a aumentar a produtividade, e viabilizam a colaboração.

“Estamos passando por um momento muito importante, no qual a evolução dos ensaios clínicos converge com avanços tecnológicos sem precedentes. A Fortrea Intelligent Technology faz parte deste momento”, disse o Diretor de Informações, Alejandro Martinez Galindo. “Com base em décadas de experiência no setor e na contribuição direta do patrocinador e do investigador, a FIT oferece soluções centradas no ser humano que possibilitam que os patrocinadores e os locais realizem ensaios de forma mais eficiente, com maior confiança e menor risco.”

Xcellerate® Ancora a Suíte Inteligente
Xcellerate®, a plataforma da Fortrea de Gestão de Qualidade Baseada em Risco (RBQM), Monitoramento Central e Supervisão, é a base da oferta FIT.

Aprimoramentos recentes proporcionam uma experiência moderna e intuitiva que integra os dados em todo o ecossistema de avaliação para fornecer insights quase em tempo real e baseados em funções. Com IA e aprendizado de máquina embarcados, a Xcellerate® analisa padrões complexos, gera sinais preditivos e inicia fluxos de trabalho automatizados, reduzindo o esforço manual e viabilizando que as equipes se concentrem no julgamento humano crítico, essencial para o sucesso da pesquisa clínica.

“Esperamos que estes aprimoramentos da Xcellerate® e a mais ampla abrangência da plataforma FIT, venham a ser um divisor de águas para as nossas equipes de estudo e para os nossos clientes”, disse Mark Morais, Diretor de Operações e Presidente de Desenvolvimento Clínico. “Por meio da incorporação do uso responsável e ético da IA, essas tecnologias viabilizam um ecossistema de pesquisa mais robusto e a capacidade de responder com maior agilidade ao que os dados nos revelam, fatores que, em conjunto, podem fazer toda a diferença para tratamentos capazes de transformar a vidas dos pacientes de forma mais rápida e eficiente.”

A Fortrea continua a expandir o portfólio Fortrea Intelligent Technology com soluções adicionais planejadas para lançamento futuro.

Sobre a Fortrea
A Fortrea (Nasdaq: FTRE) é fornecedora líder global de soluções para o desenvolvimento clínico para a indústria de ciências da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacêuticas, de biotecnologia, de dispositivos médicos e de diagnóstico para impulsionar a inovação na saúde que acelera terapias que mudam a vida dos pacientes. A Fortrea fornece gerenciamento de testes clínicos de fase I-IV, farmacologia clínica e serviços de consultoria. As soluções da Fortrea utilizam suas três décadas de experiência abrangendo mais de 20 áreas terapêuticas, sua dedicação ao rigor científico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada opera em cerca de 100 países, e é dimensionada para fornecer soluções focadas e ágeis para clientes de todo o mundo. Para mais informações sobre como a Fortrea está agilizando o desenvolvimento de medicamentos visite a Fortrea.com e siga-nos no LinkedIn, X e Bluesky.

Contatos da Fortrea:
Jennifer Minx (Mídia) – 919-410-4195, [email protected]
Kate Dillon (Mídia) – 646-818-9115, [email protected]
Tracy Krumme (Investidores) – 984-385-6707, [email protected]


GLOBENEWSWIRE (Distribution ID 9685923)

Fortrea dévoile Fortrea Intelligent Technology™ : une technologie destinée à permettre aux investigateurs et aux centres d’essais cliniques de mener des essais plus intelligents et mieux intégrés

Points clés :

  • Une solution conçue pour révolutionner les processus liés aux essais cliniques en collaboration avec les investigateurs, les centres et les équipes de recherche
  • Des technologies axées sur les personas et optimisées par l’IA automatisent les flux de travail et rationalisent la supervision afin d’améliorer la rapidité, la prévisibilité et la qualité des essais cliniques
  • Cette offre s’appuie sur Xcellerate®, la plateforme phare de Fortrea, pour fournir des informations en temps quasi réel et adaptées aux différents profils

DURHAM, Caroline du Nord, 08 avr. 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE), une organisation de recherche clinique (CRO) de premier plan à l’échelle mondiale, a dévoilé aujourd’hui Fortrea Intelligent Technology™(FIT), une suite de solutions technologiques innovantes conçues pour révolutionner les processus d’essais cliniques.

En intégrant des solutions axées sur les personas et optimisées par l’IA qui automatisent les flux de travail, rationalisent la supervision et améliorent la productivité, FIT permet aux investigateurs, aux centres d’investigation et aux équipes de projet de Fortrea de mener à bien les essais cliniques plus rapidement, avec davantage de prévisibilité, de souplesse et de qualité.

Une suite innovante et intelligente de solutions cliniques
FIT englobe des améliorations majeures apportées aux offres Fortrea éprouvées, notamment la plateforme primée Xcellerate®, ainsi que des technologies inédites conçues pour intégrer l’ensemble des processus au sein de l’écosystème des essais cliniques.

Cette suite propose des applications destinées aux clients des secteurs biopharmaceutique et biotechnologique dans les domaines de la pharmacologie et du développement cliniques, ainsi que du développement de dispositifs médicaux. Elle peut être déployée selon des modèles de services complets ou fonctionnels, certains composants étant disponibles sous forme de logiciel en tant que service (SaaS).

Les solutions FIT s’articulent autour de trois axes :

  • Cycle de vie : accélérer la conduite des essais cliniques en toute confiance
    Des solutions permettant aux investigateurs et aux centres de faire progresser les essais cliniques à chaque étape du parcours de développement clinique. Ces solutions contribuent à accélérer le processus des essais cliniques en automatisant les étapes clés, de la phase préalable à la mise en place de réseaux autonomes TMF.
  • Prospective : transformer les données en informations exploitables
    Des solutions permettant de transformer les données en perspectives d’avenir, afin de faciliter une prise de décision plus rapide et une gestion proactive des risques. Ces solutions garantissent la clarté, l’analyse des tendances et la gestion des risques grâce à des tableaux de bord intuitifs favorisant la prise de décisions éclairées en temps quasi réel et une supervision simplifiée.
  • Complémentarité : donner aux équipes de recherche les moyens de travailler plus intelligemment
    Des solutions axées sur les personas et optimisées par l’IA favorisant des processus d’essais cliniques plus productifs et plus efficaces. Ces solutions contribuent à rationaliser la diffusion des travaux de recherche, à améliorer la productivité et à faciliter la collaboration.

« Nous vivons une période historique, où évolution des essais cliniques va de pair avec progrès technologiques. Du jamais vu ! Fortrea Intelligent Technology est au cœur de cette convergence », a déclaré Alejandro Martinez Galindo, directeur des systèmes d’information. « Fort de plusieurs décennies d’expérience dans le secteur et grâce aux contributions directes des promoteurs et des centres d’essais cliniques, FIT propose des solutions centrées sur l’humain permettant aux promoteurs et aux centres de mener leurs essais cliniques plus efficacement, plus sereinement et à moindre risque. »

Xcellerate® constitue le pilier de la suite Intelligent
Xcellerate®, la plateforme de Fortrea dédiée à la gestion de la qualité axée sur la gestion des risques (RBQM), à la surveillance centralisée et à la supervision, repose sur le concept de l’offre de FIT.

Les dernières améliorations ont permis d’offrir une expérience moderne et intuitive qui intègre les données de l’ensemble de l’écosystème des essais cliniques afin de fournir des informations en temps quasi réel et adaptées à chaque profil. Grâce à l’intelligence artificielle et à l’apprentissage automatique intégrés, Xcellerate® est capable d’analyser des schémas complexes, de générer des signaux prédictifs et de mettre en place des flux de travail automatisés, réduisant ainsi les tâches manuelles et permettant aux équipes de se concentrer sur le discernement humain indispensable à la réussite de la recherche clinique.

« Nous sommes convaincus que ces améliorations apportées à Xcellerate® et à la plateforme FIT dans son ensemble vont changer la donne pour nos équipes de recherche et nos clients », a déclaré Mark Morais, directeur des opérations et président du développement clinique. « En intégrant une utilisation responsable et éthique de l’IA, ces technologies renforcent l’écosystème de la recherche et permettent de réagir plus rapidement aux enseignements tirés des données, ce qui peut faire toute la différence et permettre aux patients de bénéficier plus rapidement et plus efficacement de traitements susceptibles de changer leur vie. »

Fortrea poursuit l’élargissement de son portefeuille Fortrea Intelligent Technology, et prévoit de commercialiser de nouvelles solutions prochainement.

À propos de Fortrea
Fortrea (Nasdaq : FTRE) est un fournisseur mondial de premier plan de solutions de développement clinique pour le secteur des sciences de la vie. Fortrea s’associe à des sociétés établies et émergentes du domaine biopharmaceutique, de la biotechnologie des dispositifs médicaux et des diagnostics pour stimuler l’innovation en matière de santé, et accélérer la mise au point de traitements révolutionnaires pour les patients. Fortrea propose des services de gestion d’essais cliniques de phase I à IV, de pharmacologie clinique et de consulting. Nos solutions s’appuient sur 30 ans d’expérience dans 20 disciplines thérapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un solide réseau de centres de recherche. Notre équipe talentueuse et diversifiée, qui travaille dans une centaine de pays, est dimensionnée pour fournir des solutions ciblées et flexibles à nos clients, partout dans le monde. Pour en savoir plus sur la manière dont Fortrea optimise le développement de médicaments, rendez-vous sur Fortrea.com et suivez-nous sur LinkedIn, X et Bluesky.

Contacts Fortrea :
Jennifer Minx (Médias) – 919-410-4195, [email protected]
Kate Dillon (Médias) – 646-818-9115, [email protected]
Tracy Krumme (Investisseurs) – 984-385-6707, [email protected]


GLOBENEWSWIRE (Distribution ID 9685923)

Bitdeer Launches SEALMINER A4 Series Bitcoin Mining Rigs, Achieves a Power Efficiency of 9.45 J/TH

SINGAPORE, April 07, 2026 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR), a world-leading technology company for AI and Bitcoin mining infrastructure, today announced the launch of its latest self-developed mining machines, the SEALMINER A4 series. This generation integrates Bitdeer's proprietary SEAL04 chips, leveraging advanced process nodes to set competitive benchmarks in performance. The launch marks the successful fulfillment of Bitdeer’s previously announced technology roadmap, underscoring its commitment to long-term R&D objectives.

The new series includes three models designed for diverse deployment environments: the air-cooling A4 Pro Air, and two hydro-cooling models, the A4 Pro Hydro and A4 Ultra Hydro.

Key specifications for SEALMINER A4 series*:

  • A4 Ultra Hydro: 9.45 J/TH | 886 TH/s | 8372.7 W
  • A4 Pro Hydro: 10.9 J/TH | 680 TH/s | 7412 W
  • A4 Pro Air: 10.9 J/TH | 336 TH/s | 3662.4 W

Achieving a technical milestone of 9.45 J/TH, the A4 series is designed to enhance energy efficiency and assist operators in managing overhead. Beyond energy metrics, the lineup is engineered for consistent machine stability. Its hardware architecture is optimized for large-scale operations, aiming to improve uptime and reduce operational interruptions.

Furthermore, the series maintains the SEALMINER brand’s signature low-noise profile. The advanced hydro-cooling system enables efficient thermal management, facilitating reliable performance even in high-density environments.

Bitdeer remains dedicated to advancing transparency and efficiency in the mining industry through continuous R&D investment and technological innovation. By upholding the principles of “Innovation, Efficiency, and Stability,” Bitdeer continues to provide global miners with high-quality, reliable mining solutions and services.

*Note: Product performance may vary by ±5% in power efficiency and ±10% in hashrate and power consumption. Final specifications are based on the delivered units.

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for AI and Bitcoin mining infrastructure. Bitdeer is committed to providing comprehensive Bitcoin mining solutions for its customers and building AI computational infrastructure to support the AI revolution. Bitdeer handles complex processes involved in computing such as equipment procurement, transport logistics, data center design and construction, equipment management, and daily operations. Bitdeer also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed data centers across multiple countries, including the United States, Norway, Bhutan, and Ethiopia.

About SEALMINER

SEALMINER, a pioneering brand of mining machines under Bitdeer Technologies Group (NASDAQ: BTDR), specializes in offering efficient and sustainable mining solutions. SEALMINER integrates Bitdeer's self-developed SEAL series of mining chips manufactured using advanced process nodes. By continuously improving power efficiency ratios, SEALMINER is dedicated to providing innovative, efficient, and reliable products and services to customers worldwide. To learn more, visit https://www.bitdeer.com/ or follow Bitdeer on X @BitdeerOfficial and LinkedIn @Bitdeer.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “could,” “expect,” “intend,” “may,” “plan,” “should,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among others, statements regarding the expected performance, efficiency, deployment, mining output, or potential returns relating to Bitdeer’s products. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to, changes in cryptocurrency market prices, network difficulty and global hash rate, mining pool performance, electricity costs, operating conditions, regulatory developments, supply chain constraints, technological performance of the products, as well as potential risks, uncertainties and other factors discussed in the section entitled “Risk Factors” in Bitdeer’s annual report on Form 20-F, as well as those discussed in Bitdeer’s subsequent filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond Bitdeer’s control. Any forward-looking statements contained in this press release speak only as of the date hereof. Bitdeer specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

Contacts

For Promotional Partnerships
[email protected]

For Sales Consultations:
[email protected]

Public Relations
[email protected]

Investor Relations
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f265c82c-ecd2-414d-9171-497549cb67f2


GLOBENEWSWIRE (Distribution ID 9685251)

Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials

Highlights:

  • Designed to transform clinical trial operations for sponsors, sites and study teams
  • Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and quality
  • Builds on Fortrea’s flagship platform Xcellerate® to deliver near-real-time, role-based insights

DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial operations.

By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversight and elevate productivity, FIT helps enable sponsors, investigator sites and Fortrea project teams to deliver trials faster, with greater predictability, agility and quality.

An Innovative, Intelligent Suite of Clinical Solutions
FIT encompasses major enhancements to familiar Fortrea offerings, including the award-winning Xcellerate® platform, along with newly launched solutions designed to integrate all processes within the trial ecosystem.

The suite boasts applications for biopharma and biotech customers across clinical pharmacology, clinical development and medical device development, and it can be deployed in both full service and functional service models, with select components available as software-as-a service (SaaS).

FIT solutions are arranged into three pillars:

  • Lifecycle: Deliver Trials Faster with Confidence
    Solutions that help sponsors and sites progress clinical trials throughout each step of the clinical development journey. They help accelerate clinical trials by automating key steps, from pre-award to final eTMF.
  • Foresight: Turn Data into Actionable Insights
    Solutions that transform data into foresight, helping enable faster decision-making and proactive risk mitigation. They provide clarity, trend analysis and risk mitigation through intuitive dashboards that empower confident, near-real-time decisions and simplified oversight.
  • Companion: Empowering Study Teams to Work Smarter
    Persona-driven, AI-powered solutions that support more productive and efficient clinical trial operations. They help streamline study delivery, help boost productivity and enable collaboration.

“We are at a remarkable moment in time, where the evolution of clinical trials is converging with unprecedented advancements in technology. Fortrea Intelligent Technology sits at this nexus,” said Chief Information Officer Alejandro Martinez Galindo. “Built on decades of industry experience and direct sponsor and investigator site input, FIT delivers human-centered solutions that enable sponsors and sites to conduct trials more efficiently, with greater confidence and lower risk.”

Xcellerate® Anchors the Intelligent Suite
Xcellerate®, Fortrea’s platform for Risk-Based Quality Management (RBQM), Central Monitoring and Oversight, is the foundation of the FIT offering.

Recent enhancements deliver a modern, intuitive experience that integrates data across the trial ecosystem to provide near-real-time, role-based insights. With embedded AI and machine learning, Xcellerate® can analyze complex patterns, generate predictive signals and initiate automated workflows, reducing manual effort and enabling teams to focus on the critical human judgment required for successful clinical research.

“We expect these Xcellerate® enhancements and the broader FIT platform will be game changers for our study teams and our clients,” said Chief Operating Officer and President, Clinical Development Mark Morais. “Incorporating the responsible and ethical use of AI, these technologies enable a stronger research ecosystem and the ability to respond more quickly to what the data are telling us—all of which can make the difference in getting life-changing treatments to patients faster and more efficiently.”

Fortrea continues to expand the Fortrea Intelligent Technology portfolio, with additional solutions planned for future release.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts:
Jennifer Minx (Media) – 919-410-4195, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]
Tracy Krumme (Investors) – 984-385-6707, [email protected]


GLOBENEWSWIRE (Distribution ID 9685027)

WeRide and Uber Launch Fully Driverless Robotaxi Fare-Charging Operations in Dubai, Accelerating Autonomous Mobility in the Middle East

  • Public operations began today across Umm Suqeim and Jumeirah districts
  • Riders in Dubai can now book a WeRide fully driverless Robotaxi through the Uber app
  • Endorsed by Dubai’s Roads and Transport Authority, supporting the emirate's goal of 25% autonomous journeys by 2030

DUBAI, United Arab Emirates, March 31, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, and Uber Technologies (NYSE: UBER), today launched fully driverless Robotaxi fare-charging operations in Dubai, as part of the first batch of Level 4 Robotaxis to enter commercial service in the city. This marks a significant milestone in the companies' expanding AV partnership and strengthens their roles in supporting Dubai's driverless ambitions of 25% autonomous journeys by 2030.

WeRide's Robotaxi GXR fleet in Dubai

Public commercial operations began today without a vehicle operator on board along routes in Jumeirah and Umm Suqeim, two of Dubai’s most popular coastal tourist districts, in partnership with the Roads and Transport Authority (RTA). Riders can book and be matched with a WeRide Robotaxi through the ‘Autonomous’ option on the Uber app. Tawasul, a leading mobility and fleet operator in the UAE, will be the service operator for WeRide vehicles on the Uber platform, providing fleet management services.

The launch follows a successful supervised trial service that began in December 2025. The RTA subsequently granted WeRide a driverless vehicle trial permit in February 2026, allowing fully driverless Robotaxis to be deployed across multiple areas in Dubai, including:

  • Commercial and industrial districts: Dubai Silicon Oasis, Dubai Investment Park Second, Jabal Ali Industrial First
  • Suburban areas: Nad Al Sheba, Wadi Al Safa, Warsan, Ras Al Khor
  • Maritime trade hub: Al Hamriya Port

These districts represent some of Dubai's busiest transport, logistics, and commercial activity zones. Under the RTA's guidance, WeRide will progressively extend service into these areas, bringing fully driverless mobility to more communities. This move reinforces the UAE’s smart mobility agenda and deepens WeRide’s long-term collaboration with the RTA, while supporting the company’s roadmap for tens of thousands of Robotaxis globally by 2030.

“WeRide is committed to long-term operations in Dubai and will continue expanding our local fleet. In challenging times, we stay focused on stability and service, ensuring our Robotaxis continue to deliver safe, dependable mobility for residents. This milestone reflects the combined strength of WeRide's advanced technology, our dedicated partners, and the regulatory confidence shown by RTA, as Dubai becomes one of the first cities worldwide to operate a fully driverless commercial Robotaxi service,” said Dr. Tony Han, Founder and CEO of WeRide.

“Bringing fully driverless vehicles to Dubai is an important milestone in making autonomous mobility a global reality. This launch underscores our deep commitment to the UAE and our vision for a hybrid world—where drivers and AVs operate side-by-side to create a more resilient network. Especially during challenging times in the region, we are proud to be a partner to this city, ensuring that Uber is always there to help people move seamlessly and with confidence,” said Sarfraz Maredia, Global Head of Autonomous Mobility & Delivery at Uber.

Earlier this week, Uber disclosed through public filings that it beneficially owns approximately 5.82% of WeRide's Class A ordinary shares. As a global leading mobility platform, Uber's stake demonstrates strong confidence in WeRide's technological leadership, global commercialization capabilities, and long-term strategic synergy value.

In 2023, WeRide became the first company in the UAE to receive a national license covering all types of self-driving vehicles, permitting autonomous testing and operation on public roads across the country, subject to emirate-level approvals. In February 2026, WeRide and Uber committed to deploy at least 1,200 Robotaxis across the Middle East spanning Dubai, Abu Dhabi, and Riyadh. Today, WeRide has over 200 Robotaxis in the Middle East. Since 2025, WeRide's Middle Eastern subsidiary has achieved operational profitability in its Robotaxi business.

About WeRide
WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 40 cities across 12 countries. We are also the first and only technology company whose products have received autonomous driving permits in eight markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune's 2025 Change the World and 2025 Future 50 lists.

Media Contact
[email protected]

Safe Harbor Statement
This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3d8c51b6-b0ac-47b8-b097-46e2d808f315


GLOBENEWSWIRE (Distribution ID 9681639)

TTEC Expands Cairo Operations with Major Hiring Initiative to Support Global Growth

CAIRO, March 31, 2026 (GLOBE NEWSWIRE) — TTEC, a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience (CX), today announced a major hiring initiative in Cairo, with plans to add more than 330 new team members by the end of April 2026.

Scaling to Meet Rising Global Demand

TTEC’s Cairo site supports more than 500 employees delivering services in 11 languages. This hiring initiative reflects growing global client demand for TTEC’s multilingual, AI-enabled CX services and cements Cairo’s role as one of the company’s fastest-scaling strategic delivery hubs worldwide.

Since entering Egypt in 2023, the company has rapidly grown its presence, including opening a state-of-the-art facility in Maadi Technology Park in early 2025. In November 2025, the company signed a Memorandum of Understanding with Egypt’s Information Technology Industry Development Agency to scale its Cairo workforce to more than 4,000 employees by 2029.

“Because we’re in an expansion mode, this means there is ample opportunity for personal career growth in an inclusive and multicultural environment,” said Manno Ragab, executive director of TTEC’s Egypt operations. “TTEC is known for developing talent from within, with more than two-thirds of leadership roles filled internally, offering employees a clear path for career advancement.”

For two years in a row, TTEC Egypt has been certified as a Great Place to Work®, which is based entirely on employee feedback collected through the organization’s annual Trust Index™ survey. Additionally, TTEC’s Cairo facility serves as an innovation hub for next-generation CX and AI-enabled solutions. Employees gain hands-on experience with AI tools, cloud platforms, and advanced customer engagement technologies.

Hiring Multilingual Talent to Power Global CX Delivery

TTEC is currently hiring for customer service and bilingual sales roles across multiple language combinations such as French, German, Italian, Dutch, Spanish, Portuguese, and Turkish, paired with English. Candidates interested in joining TTEC’s growing Cairo team can explore open roles and apply at TTECjobs.com.

About TTEC

TTEC Holdings, Inc. (NASDAQ: TTEC) is a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI and customer experience. Serving iconic and disruptive brands, TTEC’s outcome-based solutions span the entire enterprise, touch every virtual interaction channel, and improve each step of the customer journey. Leveraging next-generation digital technology, the Company’s TTEC Digital business designs, builds, and operates omnichannel contact center technology, CRM, AI, and analytics solutions. The Company also delivers AI-enhanced customer engagement, customer acquisition and growth, tech support, back-office, and fraud prevention services. Founded in 1982, the Company’s employees operate on six continents and bring technology and humanity together to deliver happy customers and differentiated business results. To learn more, visit https://www.ttec.com/.

Media Contact:
Meredith Matthews
[email protected] 


GLOBENEWSWIRE (Distribution ID 9681398)

Zoom AI Companion 3.0 Empowers Workers to Reclaim Time, Backed by New Research on Lost Lunch Breaks

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) — Today, Zoom Communications Inc. (NASDAQ: ZM) enters the next phase of its Zoom Ahead campaign with Take Back Lunch, a cultural movement designed to help workers reclaim time in their day, starting with lunch. The initiative brings together new research in partnership with Morning Consult, product innovation powered by Zoom AI Companion 3.0, and an experiential activation in New York City to show productivity gains in action.

A new national study conducted by Morning Consult on behalf of Zoom found that 60% of U.S. knowledge workers squeeze in a short lunch between meetings or tasks, 35% skip lunch at least once per week, and three in four regularly eat at their desks while actively working. Heavy workloads (63%) and meetings scheduled over lunch (54%) are the biggest contributors to lost lunch time. And in the era of video-first work, nearly three in four workers (72%) say they would rather skip lunch than eat on camera during a meeting.

Making Productivity Tangible

“While much of the conversation around AI focuses on future potential, most teams are still dealing with a very present challenge: time lost to fragmented tools and manual follow-through,” said Kimberly Storin, Chief Marketing Officer at Zoom. “Zoom’s AI Companion 3.0 automates what happens before, during, and after meetings so teams can reclaim time in their day. ‘Take Back Lunch' is designed to make a broader shift visible. When AI is embedded into the flow of work, time isn’t just saved, it’s returned to people.”

Zoom AI Companion is an agentic AI assistant that automates tasks, connects workflows, and helps teams move from conversation to execution across Zoom Workplace. Key capabilities include:

  • Automated meeting summaries and decision capture: Instantly generates notes, highlights, and action items so teams can stay aligned without manual follow-up.
  • Cross-platform context unification: Connects to data from meetings, messages, files, and third-party apps to provide a single, intelligent view of work.
  • Proactive task management and follow-up generation: Identifies next steps, assigns tasks, and keeps projects moving with less manual coordination.
  • Real-time insights and intelligent assistance across Zoom Workplace: Embedded across Zoom Workplace, including meetings, chat, and phone, and available on the web at ai.zoom.us for easy access to AI insights throughout the workday.

The Morning Consult study underscores the opportunity for workers when they use AI tools:

  • 76% of workers who use AI tools report saving at least 30 minutes per day, including 43% who save an hour or more.
  • Nearly 3 in 4 (73%) say they would use time saved by AI to take a dedicated lunch break.
  • 66% are open to using AI-powered meeting tools, such as automated notes and smart recaps, to skip meetings that conflict with lunch.
  • 70% believe AI tools can help restore their work-life balance.

Introducing the Hard Stop Burger Shop

To bring the movement to life, Zoom will open the Hard Stop Burger Shop, a speakeasy style burger pop-up inside a Manhattan office building, from March 25 – March 27.

Time slot reservations open to the public can be made at takebacklunch.nyc.

Beyond the days of the activation, workers can join the movement to “Take Back Lunch” at zoomahead.com/lunch. The goal: Reclaim 1 million lunches by encouraging workers to commit to protecting their break time, demonstrating how AI-powered productivity can translate into meaningful human outcomes.

A Cultural Signal Within Zoom Ahead

Take Back Lunch builds on Zoom Ahead, Zoom’s largest brand campaign to date, which reflects a broader truth about work today: there are more tools than ever, yet work often feels more fragmented and less human. Zoom Ahead positions Zoom as an AI-first workplace platform built to connect people to progress. What started as the best way to meet has evolved into a system of action for modern work, reducing friction, unifying workflows, and embedding agentic AI directly into the daily flow of collaboration.

Survey Methodology
This survey was conducted online by Morning Consult on behalf of Zoom between February 17 – March 3, 2026, among a national sample of 1,047 U.S. knowledge workers. Oversamples were collected in New York City (276), San Francisco (166), Chicago (224), Dallas (217), Atlanta (202), and Denver (105). Results from national data have a margin of error of +/- 3 percentage points; oversample data have margins of error of +/- 6–10 percentage points.

About Zoom
Zoom (NASDAQ: ZM) is a system of action for modern work, turning live collaboration into completed results. From entrepreneurs to global enterprises, customers choose Zoom to seamlessly collaborate, communicate, and drive outcomes across meetings, phone, contact center, and more — all with the built-in assistance of Zoom AI Companion. Founded in 2011, Zoom is headquartered in San Jose, CA. For more information, visit zoom.com.

Media Contact
Rebecca Bernhard
[email protected]
[email protected]


GLOBENEWSWIRE (Distribution ID 9678380)

Publication relative à des notifications de transparence

INFORMATION RÉGLEMENTÉE

Publication relative à des notifications de transparence

Mont-Saint-Guibert (Belgique), le 20 mars 2026, 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci-dessous.

Robert Taub / Robelga SRL

Le 19 mars 2026, Nyxoah a reçu une notification de transparence de Robert Taub et d’une personne liée, Robelga SRL, à la suite du franchissement à la hausse du seuil de 3% par Robelga SLR le 30 décembre 2025 (sans modification de la participation globale du “groupe”). Sur la base de la notification, Robert Taub (avec ses entreprises contrôlées) détenait 4.360.800 droits de vote, soit 4.310.800 droits de vote attachés à des titres et 50.000 instruments financiers assimilés, représentant 10,14% du nombre total des droits de vote en date du 30 décembre 2025 (43.026.460).

La notification datée du 19 mars 2026 contient les informations suivantes :

  • Motif de la notification : acquisition ou cession de titres conférant le droit de vote ou de droits de vote
  • Notification par : une entreprise mère ou une personne détenant le contrôle
  • Personnes tenues à la notification :
    • Robert Taub
    • Robelga SRL (avec adresse à Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
  • Date du dépassement de seuil : le 30 décembre 2025
  • Seuil franchi : 3%
  • Dénominateur : 43.026.460
  • Détails de la notification :
A) Droits de vote Notification précédente Après la transaction
  # droits de vote # droits de vote % de droits de vote
Détenteurs de droits de vote   Attachés à des titres Non liés à des titres Attachés à des titres Non liés à des titres
Robert Taub 2.712.510 2.712.510 0 6,30% 0,00%
BMI Estate 567.484 0 0 0,00% 0,00%
Robelga SRL 1.030.806 1.598.290 0 3,71% 0,00%
Sous-total 4.310.800 4.310.800   10,02%  
  TOTAL 4.310.800 0 10,02% 0,00%

B) Instruments financiers assimilés Après la transaction
Détenteurs d’instruments financiers assimilés Type d’instrument financier Date d’échéance Date ou délai d’exercice ou de conversion # droits de vote pouvant être acquis en cas d’exercice de l’instrument % de droits de vote Règlement
Robert Taub Droits de souscription 08/06/2027   25.000 0,06% en espèces
Robert Taub Droits de souscription 14/06/2028   25.000 0,06% en espèces
  TOTAL     50.000 0,12%  

  TOTAL (A & B) # droits de vote % de droits de vote  
        4.360.800 10,14%  
  • Chaine des entreprises contrôlées par l'intermédiaire desquelles la participation est effectivement détenue : Robelga SRL est 100% propriété de BMI Estate (société simple sans personnalité juridique). Robert Taub a 100% l'usufruit et les enfants de Robert Taub ont 100% la nue-propriété de BMI Estate.
  • Information supplémentaire : Cette notification était requise en raison du dépassement à la hausse du seuil de 3% par Robelga SRL.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001171212)

Publication relating to transparency notifications

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), March 20, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

Robert Taub / Robelga SRL

On March 19, 2026, Nyxoah received a transparency notification from Robert Taub and related person Robelga SRL, following the crossing above the 3% threshold by Robelga SRL on December 30, 2025 (while the overall “group” participation did not change). Based on the notification, Robert Taub (together with his controlled undertakings) held 4,360,800 voting rights, consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 10.14% of the total number of voting rights on December 30, 2025 (43,026,460).

The notification dated March 19, 2026 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Robert Taub
    • Robelga SRL (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
  • Date on which the threshold was crossed: December 30, 2025
  • Threshold that is crossed: 3%
  • Denominator: 43,026,460
  • Notified details:
A) Voting rights Previous notification After the transaction
  # of voting rights # of voting rights % of voting rights
Holders of voting rights   Linked to securities Not linked to the securities Linked to securities Not linked to the securities
Robert Taub 2,712,510 2,712,510 0 6.30% 0.00%
BMI Estate 567,484 0 0 0.00% 0.00%
Robelga SRL 1,030,806 1,598,290 0 3.71% 0.00%
Subtotal 4,310,800 4,310,800   10.02%  
  TOTAL 4,310,800 0 10.02% 0.00%

B) Equivalent financial instruments After the transaction
Holders of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
Robert Taub Warrants 08/06/2027   25,000 0.06% cash
Robert Taub Warrants 14/06/2028   25,000 0.06% cash
  TOTAL     50,000 0.12%  

  TOTAL (A & B) # of voting rights % of voting rights  
        4,360,800 10.14%  
  • Full chain of controlled undertakings through which the holding is effectively held: Robelga SRL is 100% owned by BMI Estate (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of BMI Estate.
  • Additional information: This notification was due because Robelga SRL moved above the 3% threshold.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001171212)